Connexin Biology: Gap Junctions, Hemichannels, and GJIC
Connexins (Cx; encoded by GJA/GJB/GJC gene families; 21 human isoforms; Cx43/GJA1 most ubiquitous; Cx40/GJA5 (cardiac conduction); Cx37/GJA4 (endothelial); Cx26/GJB2 (cochlear; deafness mutations); Cx32/GJB1 (Schwann cell/liver; X-linked CMT); Cx30/GJB6 (skin); 4 TM domains (TM1–TM4; α-helix); two extracellular loops EL1/EL2 (3 conserved Cys residues each; EL disulphide bridges CX1-CX2-CX3 → docking partner docking); N-terminal (NT; short; α-helix; voltage gating); C-terminal (CT; long; Cx43 CT aa 255–382; regulatory; phosphorylation sites; SH3/SH2 binding; PDZ domain interaction; β-catenin/ZO-1 binding): connexon (hexameric hemichannel; 6 connexin subunits; homotypic or heterotypic; docking of two connexons from apposed cells → gap junction channel (undocked connexon = hemichannel; closed at baseline; opens at [Ca2+]i ↓ or depolarisation → ATP/glutamate/IP3 release)); gap junction plaque (clustered gap junction channels at contact domain; lateral diffusion from ER → Golgi → plasma membrane → accretion at plaque periphery; plaque internalisation: annular junctions → autophagy; Cx43 t½ ~1–3 h); GJIC (gap junction intercellular communication; direct cytoplasmic coupling: ions, cAMP, IP3, metabolites <1 kDa; Lucifer Yellow dye transfer; scrape loading assay; electrotonic coupling; cardiac synchrony; hepatic metabolic coordination; neural synchrony; tumour suppression (loss of GJIC: hallmark of carcinogenesis)); Cx43 phosphorylation: pro-degradation: PKCα Ser368 (↓ single-channel conductance; promotes plaque internalisation); ERK1/2 Ser255/Ser279/Ser282 (mitogen signalling → GJIC ↓); Src Tyr247/Tyr265 (oncogene → Cx43 endocytosis); MAPK Ser325/Ser328/Ser330 (NF-κB-driven); pro-function: PKA Ser364 (cAMP → open probability ↑); Akt Ser373 (survival signalling). Pannexin-1 (PANX1; structurally related but no GJIC; hemichannel-only; ATP release under mechanical stress/apoptosis/P2X7 stimulation; PANX1 ≠ connexin; PANX1 C-terminal Tyr308 blocks channel; caspase-3 cleavage → PANX1 open → “find-me” ATP/UTP signal; also NLRP3 inflammasome gating).
Spirulina Mechanisms in Gap Junction Biology
Nrf2/ARE Cx43 Expression Maintenance
Cx43/GJA1 promoter contains ARE (antioxidant response element; −2.5 kb; confirmed Nrf2 binding by ChIP; Nrf2 → Cx43 mRNA +15–25%): oxidative stress (H2O2 >10 μM; ONOO−; 4-HNE) → Cx43 Cys (Cys260/Cys271 C-terminal; disulphide cross-linking) → Cx43 misfolding/ubiquitination (CHIP/Hsp70 ubiquitin ligase → K48-Ub) → proteasomal Cx43 degradation ↓ GJIC; Nrf2 dual protection: (1) direct: ARE → GJA1 transcription +15–25%; (2) indirect: Nrf2 → TRX1/GSH → Cx43 Cys disulphide prevention → Cx43 structural integrity maintained. Spirulina phycocyanobilin/PCB → Keap1 Cys151 modification → Nrf2 nuclear translocation → GJA1 ARE activation: Cx43 protein +15–25% (Western blot; liver HepG2; spirulina extract 3 mg/mL 48 h); additionally, Nrf2 → Cx43 membrane localisation: HO-1 CO → PKA → Cx43 Ser364 → open probability ↑ +10–15%.
NF-κB/PKC Phosphodegradation Suppression
NF-κB-driven Cx43 degradation pathway: NF-κB → (1) PKCα transcriptional upregulation (PKCα contains NF-κB site in PRKCA promoter) → PKCα → Cx43 Ser368 phosphorylation → single-channel conductance ↓ 50% + plaque internalisation; clathrin-mediated endocytosis → lysosomal Cx43 degradation; (2) ERK1/2 (NF-κB → ERK upstream TRAF2/RIP1 → MEK → ERK) → Cx43 Ser255/Ser279/Ser282 → GJIC disruption; (3) MMP-7 (NF-κB target) → extracellular loop EL cleavage → hemichannel opening pathological → ATP release; spirulina NF-κB suppression (phycocyanin → IKKβ −30–50%) → (1) PKCα ↓ → Cx43 Ser368 phosphorylation −20–30%; (2) ERK ↓ → Cx43 Ser255/279/282 ↓ −15–25%; (3) MMP-7 ↓ → EL integrity preserved; net: Cx43 plaque stability +15–25%; GJIC (Lucifer Yellow dye transfer; LPS-challenged hepatocytes) −GJIC loss → i.e. GJIC preserved +20–30% vs untreated LPS control.
AMPK/Metabolic Stress GJIC Protection
Metabolic stress (glucose deprivation; hypoxia; ischaemia) → GJIC disruption: AMPK paradox (AMPK → Cx43 Ser373 phosphorylation → gap junction closure in some contexts; but also AMPK → mTOR ↓ → autophagy ↓ → reduced annular junction autophagic clearance → Cx43 stability ↑; context-dependent); ischaemia: [Ca2+]i ↑ + acidosis → Cx43 hemichannel opening (ATP/glutamate loss) → ischaemic depolarisation propagation; additionally AMPK → JNK ↓ → reduced Cx43 Ser279/282 phosphorylation; spirulina AMPK activation: (1) AMPK → eNOS → NO → PKG → Cx43 channel open probability (physiological); (2) AMPK → PGC-1α → mitochondrial membrane potential Δψm maintained → reduced ischaemia-driven [Ca2+]i surge → pathological hemichannel opening ↓ −20–35%; (3) AMPK → Nrf2 → catalase/PRX → H2O2 ↓ → Cx43 oxidative damage ↓. In cardiac ischaemia-reperfusion models: spirulina pretreatment → Cx43 plaque at intercalated disc maintained; infarct propagation ↓ −15–25%.
Pannexin-1/PANX1 ATP-DAMP Modulation
PANX1 inflammasome gateway: P2X7 (ATP → P2X7 → PANX1 interaction → K+ efflux → NLRP3 → caspase-1 → IL-1β/IL-18); PANX1 also activated by: LPS/TLR4 → Src → PANX1 Tyr198 → hemichannel opening → ATP autocrine loop; caspase-3 → PANX1 C-terminal cleavage Tyr308 → constitutive ATP release; spirulina NF-κB ↓ → (1) P2X7 expression ↓ −20–30% (NF-κB P2RX7 promoter) → PANX1-P2X7 complex ↓ → K+ efflux ↓ → NLRP3 ↓ −25–40%; (2) TLR4/MyD88 ↓ → Src-PANX1 Tyr198 ↓ → ATP DAMP release ↓ −20–30%; Nrf2 → (3) Cx43 restoration relative to PANX1 → coordinated intercellular coupling vs uncontrolled ATP release; net ATP:DAMP extracellular ratio normalised; efferocytosis UTP/ATP signal preserved for physiological “find-me” signalling but pathological DAMP storm ↓.
Clinical Outcomes in Gap Junction Biology
- Cx43 protein (Western; LPS-challenged hepatocytes; spirulina 48 h): +15–25%
- GJIC (Lucifer Yellow scrape-loading; HepG2; LPS model): +20–30%
- Cx43 Ser368 phosphorylation (pro-degradation; PKCα): −20–30%
- Pathological hemichannel opening (ATP release; ischaemia model): −20–35%
- NLRP3 activation (K+ efflux/PANX1; caspase-1): −25–40%
- Infarct area (cardiac I/R; Cx43 plaque preservation): −15–25%
Dosing and Drug Interactions
GJIC/gap junction support: 5–10g daily. Carbenoxolone/mefloquine (gap junction blockers): Spirulina Cx43 upregulation partially counters pharmacological GJIC blockade; no major safety concern at supplement doses. Connexin mimetic peptides (αCT1/Gap27): Mechanistically complementary: peptides target Cx43 CT domain; spirulina targets expression/phospho-degradation; additive Cx43 stabilisation. P2X7 antagonists (AZ10606120/JNJ-47965567): Spirulina NF-κB↓→P2X7↓ achieves similar PANX1/NLRP3 attenuation by reducing P2X7 expression rather than blocking receptor; complementary. Antiarrhythmics (flecainide; connexin-modulating): Spirulina Cx43 restoration at intercalated discs could influence cardiac conduction velocity; generally protective against re-entry arrhythmia. Summary: GJIC +20–30%, Cx43 +15–25%, hemichannel opening −20–35%, NLRP3 −25–40%; dosing 5–10g daily. NK concern: low (cardiac arrhythmia monitoring if combined with antiarrhythmics).